1350653-29-0 Usage
### Properties
1. Chemical Classification: Diamine
2. Core Structure: Pyrazoleand pyrimidine-based
3. Substituents:
Fluoro group (5-fluoro)
Benzyl group (2-fluorobenzyl)
Phenyldiazenyl group [(E)-phenyldiazenyl]
4. Amino Groups: Contains two amino groups
5. Biological Activity: Potential biological activity due to structural similarities with other biologically active molecules
6. Chemical and Physical Properties:
Presence of fluorine
Presence of aromatic groups
Complex structure suggests potential for interesting chemical and physical properties
7. Potential Applications:
Pharmaceutical research
Materials science research
Core Structure
Pyrazolo[3,4-b]pyridin-3-yl
Pyrimidine-4,6-diamine
Substituent Details
Fluoro group at position 5 on the core structure
Benzyl group attached to the pyrazole ring at position 1
Phenyldiazenyl group attached to the pyrimidine ring, with an E configuration
Amino Groups
Present at positions 4 and 6 on the pyrimidine ring
Biological Activity
Structural similarities with biologically active molecules suggest potential pharmacological relevance or bioactivity
Chemical and Physical Properties
Fluorine incorporation can alter reactivity and polarity
Aromatic groups contribute to stability and potential π-π interactions
Potential Applications
Pharmaceutical research: Drug design and development
Materials science research: Synthesis of functional materials
This compound's intricate structure, containing diverse functional groups, hints at its potential for various applications in both biological and materials science fields.
Check Digit Verification of cas no
The CAS Registry Mumber 1350653-29-0 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,5,0,6,5 and 3 respectively; the second part has 2 digits, 2 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 1350653-29:
(9*1)+(8*3)+(7*5)+(6*0)+(5*6)+(4*5)+(3*3)+(2*2)+(1*9)=140
140 % 10 = 0
So 1350653-29-0 is a valid CAS Registry Number.
1350653-29-0Relevant articles and documents
PROCESS FOR PREPARING METHYL {4,6-DIAMINO-2-[5-FLUORO-1-(2-FLUOROBENZYL)-1H-PYRAZOLO[3,4-B]PYRIDIN-3-YL]PYRIMIDIN-5-YL}CARBAMATE
-
, (2022/01/05)
The present application relates to a novel and efficient process with high yield for preparing methyl {4,6- diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate of the formula (I) in the crystalline form of modification I, wherein the x-ray diffractogram of the compound of the formula (I) in modification I exhibits peak maxima of the 2 theta angle at 5.9, 6.9, 22.7, in very high purity which is significantly more cost-effective than the process known from the art and can be performed in customary pilot- and production plant-equipment (stirred tank/devices for isolation).
BICYCLIC AZA HETEROCYCLES, AND USE THEREOF
-
Paragraph 0716; 0717; 0718; 0719, (2014/06/11)
The present application relates to novel bicyclic azaheterocycles, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prophylaxis of diseases and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of cardiovascular disorders.
USE OF STIMULATORS AND ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE FOR TREATING SICKLE-CELL ANEMIA AND CONSERVING BLOOD SUBSTITUTES
-
, (2013/06/28)
The present invention relates to the novel use of stimulators and activators of soluble guanylate cyclase for the treatment of sickle cell anemia and for the preservation of blood substitutes. The present invention furthermore relates to the use of stimulators and activators of soluble guanylate cyclase in combination with PDE5 inhibitors for the treatment of sickle cell anemia and for the preservation of blood substitutes.
